Splet03. maj 2024 · Dupilumab showed acceptable safety and sustained efficacy in adults with moderate-to-severe atopic dermatitis (AD) for up to 4 years. Safety data were consistent with 52-week controlled studies and with the known safety profile of dupilumab. Splet04. feb. 2024 · HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like abscesses that can lead to open wounds and irreversible scarring in the most intimate parts of the body2,3 There is only one approved therapy for HS and many patients, even those on treatment, still experience uncontrolled symptoms4
Sustained efficacy of secukinumab in patients with …
Splet06. avg. 2024 · S As-Sanie, L Giudice, M S Abrao, K Wilk, C Mehedintu, C Becker, J C Arjona Ferreira, R B Wagman, F Wang, Q A Warsi, J Neil, O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data, Human Reproduction, Volume 36, Issue Supplement_1, July 2024, … SpletThe present invention relates to a sustained-release microsphere using a biodegradable polymer and a method for preparing same and, more particularly, to a microsphere containing entecavir and made of a biocompatible polymer and a method for preparing same. The microsphere containing entecavir according to the present invention exhibits a … clayton state athletes lounge
GD2-CART01 May Induce Sustained Antitumour Effect...
Splet04. jun. 2024 · An efficacy period for a treatment regimen is defined as the sum of all intervals of time that a subject was treated with recombinant factor IX Fc fusion protein according to that regimen, excluding major and minor surgical/rehabilitation periods and when >42 d elapsed between infusions for subjects receiving prophylaxis. SpletSustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. … Splet20. jul. 2024 · Background The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated patients achieved the primary endpoints of … clayton state academic advisors